📌 Key Takeaways
- Topic: Is Silicon Dioxide Toxic? Safety of Amorphous vs Crystalline Forms Explained
- Keywords: silica melting point
- Published: 2026-11-20 04:41:26
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Silicon Dioxide CAS 7631-86-9: Identification, Properties and Regulatory Information
- Silica 99% Purity: Specifications, Grades and Typical Applications
- 6.2.3. Oral Drug Administration
- Silica Manufacturer in China: How to Evaluate Quality, Capacity and Export Experience
- Employing DE For Health Benefits
- Silica for Sale: How to Find the Right Grade and a Reliable Seller
- 88. Ali M., Gutting B.W., Van Hoek M.L. Multiple Path Particle Dosimetry for Prediction of Mouse Lung Deposition of Nanoaerosol Particles. Int. J. Adv. Res. Eng. Technol. 2017;8:10-20. [ Google Scholar ]
- Spherical Silica Market 2026: Semiconductor Packaging Demand and Growth Outlook
- Magnetic particles were synthesized with an iron-containing coating. The model drugs were safranin O and hydrocortisone. The particles were functionalized with a bulky azo derivative to act as a gatekeeper and stop early leakage of the drug. In vitro release models have demonstrated that most of the drug is released only in the colon, as desired. This is owing to the reductive environment in the colon (the presence of the azoreductase enzyme), where the enzymatic degradation of the azo bond resulted in controlled release. In addition, in vivo pharmacokinetic studies were conducted in a rat model of induced colitis to test the effect of the magnetic field during therapy. The findings boosted when the rats wore a magnetic belt, which extended the retention time of the particles in the desired areas [ 75 ]. Zhang et al. presented a study in which magnetic silica nanoparticles (filled with sulforaphane) were developed for the treatment of myocardial infarction [ 38 ]. In mouse models, effective accumulation was observed in the infarcted zone after the application of an external magnetic field [ 33, 75 ]. These results show the potential of using magnetic particles with magnetic field guidance [ 33 ]. Radhakrishnan et al. developed a drug delivery system (DDS) loaded with carboplatin for targeted lung cancer therapy [ 63 ]. The DDS was core-shell mesoporous silica functionalized with folic acid. Initially, the drug loading capability of the functionalized carrier was more than twice as high per surface unit compared to the non-functionalized carrier due to the anchored -NH 2 groups. The drug release was sustained but limited (up to 36%) in the case of the functionalized particle, similarly to previous cases. This is most likely owing to the stronger interactions between the amine groups and the carboplatin. The amino-functionalized particles were further functionalized with folic acid to increase cellular uptake of the particles, demonstrating the potential of folic acid-targeted therapy [ 63, 65, 76 ]. Cancer cells typically overexpress folate receptors, resulting in folate-mediated internalization that preferentially targets these cells [ 63, 76 ]. This was demonstrated in a drug-mediated cytotoxicity analysis where amino- and folate-functionalized particles were evaluated and compared. Much greater cytotoxicity was observed in cells overexpressing folate receptors [ 63 ]. Similar research was carried out by Shirani et al., where folic acid functionalized MSNs were loaded with gemcitabine as a model drug, to investigate its potential in cancer treatment, while actively targeting cancer cells [ 70 ]. Outcomes have shown that higher cellular uptake (HeLa and K562 cells) was observed in the case of the functionalized particles, compared with the non-functionalized carriers [ 70 ]. Jafarpour et al. demonstrated the importance of functionalizing the carriers to accomplish targeted therapy utilizing methotrexate as a model drug [ 76 ]. The particles were grafted with a copolymer to act as a pH-responsive gatekeeper and folic acid to actively target cancer cells [ 76 ]. Ortiz et al. similarly designed a pH-responsive DDS, loaded with the anticancer drug doxorubicin [ 11 ]. The particles were functionalized with transferrin through a pH-sensitive linker as a gatekeeper, controlling the release kinetics and preventing early leakage of the drug [ 11 ]. An interesting breast cancer therapy was published by Mal et al. using doxorubicin as API and mesoporous silica as a carrier [ 65 ]. The amine-functionalized MSNs were PEGylated and then conjugated with folic acid or hyaluronic acid. It was also published that coating the nanoparticles with polydopamine (PDA) and polyethylene glycol (PEG) brings about prolonged doxorubicin release from MSNs [ 77 ]. These conjugates enabled ligand-mediated targeted drug delivery [ 65 ]. Researchers have developed a successful DDS that targets cancer cells, thus staying away from the side effects associated with doxorubicin in conventional cancer therapy. This is important because in vitro cytotoxicity studies have shown that the free drug has higher cytotoxicity than the nanocarriers [ 65 ]. Shahbaz et al. developed a redox-responsive silica nanocarrier loaded with paclitaxel to target breast cancer cells [ 67 ]. The amine-functionalized silica core was coated with disulfide-functionalized non-porous silica shell. Then the core-shell carriers were further coated with polyethylene glycol via disulfide linkages. In vitro drug release assay verified the correlation between the redox potential of the environment and the release kinetics. This is an important finding, as it has been revealed that cancer cells possess a higher redox ability than healthy cells. This provides controlled paclitaxel release for targeted therapy. According to cell uptake and cell viability assays, this DDS is noticeably more effective than free paclitaxel, making this nanocarrier an exciting prospect [ 67 ]. These illustrations highlight the importance of surface functionalization and employing stimuli-responsive gatekeepers to attain productive targeted therapy.
Silica Wholesale: How to Buy in Bulk and Get the Best Price
What is silica (SiO₂)?
cosmetic grade silica Even though MSNs can usually be recognized as secure products, their use during therapy may cause side impacts in the body [ 1, 2, 29 ]. Due to their small size and large surface area, they may tend to accumulate in the body, or certain organs (liver, spleen, kidney, lung) and may even be toxic in higher concentrations, which is a clear disadvantage [ 1, 4, 27 ]. The silanol groups (Si-OH) on their surface can interact with the phospholipid layer of the cell membrane, thereby causing cell lysis or, in extreme cases, hemolysis [ 4, 8 ]. In severe cases, the lack of hemocompatibility can also cause issues [ 2 ]. Overall, indications of cytotoxicity, haemotoxicity, and genotoxicity were also found [ 4, 8 ]. That is why the biocompatibility of all comparable preparations must be strictly controlled [ 2, 4, 27 ]. The physicochemical features (particle size, particle morphology, surface chemistry, pore structure, etc.) of nanocarriers also have a major impact on toxicity [ 2, 4, 8, 30 ]. Additionally, further attention must be paid to the biological influences of their decomposition products, because they may also cause unwanted side influences [ 1 ]. The breakdown of silica nanoparticles in the body can take up to a few days. The opening hydration is followed by hydrolysis, and, in the end, they are excreted in the urine in the form of silicic acid [ 1 ]. Nevertheless, the literature is contradictory in this regard [ 31 ]. Some experiments show no considerable cytotoxic effect [ 18, 31 ], while other experiments say otherwise [ 23, 32 ]. For example, an in vitro study was performed with multiple concentrations, surfaces, and particle sizes (60 nm, 100 nm, 300 nm) of MSNs, with an exposure time of 72 h [ 18 ]. This study shown no significant cytotoxic influence in any of the cell lines tested (human cervical (HeLA), epithelial lung (A549), and glioblastoma (U251)) [ 18 ]. Ismail et al. investigated the cytotoxic effect of silica nanoparticles in vivo in mouse models [ 33 ]. Amorphous silica nanoparticles were administered to the animals orally, at a dose of 150 mg/kg/day, for 3 months. Based on these mouse models, no toxic effects were detected under sub-chronic treatment of the nanoparticles [ 31 ]. In another study, particle size (15 nm, 60 nm, 200 nm) dependent impact was observed on cellular viability in all four cell lines tested (THP-1 derived macrophages, A549 epithelial cells, HaCaT keratinocytes, and NRK-52E kidney cells) [ 23 ]. Smaller particles caused notable toxicity on each cell line, after the exposure time of 24 h, in contrast to the larger particles, which demonstrated no cytotoxic impact [ 23 ]. A comparable outcome has been published to verify the toxic characteristic of mesoporous silica. In this in vitro study, the researchers investigated the effect of MSNs with an average size of 7 nm on cell viability at three different concentrations. After 72 h of exposure, only the highest concentration (62.5 µg/mL) caused a substantial decrease in cell viability of human lung fibroblast cells. This toxicity occurred in a time- and dose-dependent manner [ 32 ]. In an in vivo mouse model, MacCuaig et al. presented coating-dependent impacts after repeated intravenous administration of MSNs. Chitosan-coated MSNs induced minor organ changes and were the most biocompatible. Uncoated and especially PEG-coated MSNs (especially 2K PEG) moderately augmented pre-existing vascular or organ lesions, implying that PEGylation has the potential to augment chronic risks, while chitosan enables safer long-term use [ 34 ]. An in vitro study of Barguilla et al. exposed epithelial lung cells to bare, PEG-functionalized, or galacto-oligosaccharide-functionalized MSNs for eight weeks. There was no reported long-term DNA damage, but malignant-like alterations like anchorage-independent growth, boosted migration/invasion, and secretome-facilitated tumor promotion were triggered by PEG- and GAL-functionalized MSNs. Naked MSNs did not cause such alterations and were determined to be safer [ 35 ]. Coating, on the whole, exerts a significant impact on the safety of MSNs. Uncoated MSNs are relatively innocuous; the most biocompatible coatings were achieved with chitosan, but PEG and carbohydrate functionalization can be dangerous in the long run, from vascular toxicity in vivo to tumor-promoting activity in vitro [ 34, 35 ].
What is the difference between fumed silica and precipitated silica?
colloidal silica supplier 33. Zhang J., Dong Y., Liu X., Jin H., Wang S., An N., Wang L. Effective myocardial infarction treatment by targeted accumulation of Sulforaphane using porous magnetic silica nanoparticles. Int. J. Pharm. 2023;645:123389. doi: 10.1016/j.ijpharm.2023.123389. [ DOI ] [ PubMed ] [ Google Scholar ]
What drives silica raw material prices?
600 mesh silica
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.